Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.


Clinical Trial Description

Proteasome inhibitor and immunmodulators have synergistic effect for plasma cell dyscrasia. Due to the fact that more than 70-80% of patients with amyloidosis have renal involvement, the application of lenalidomide is limited. Thus, the investigators designed this open-label, multicenter, phase 2 study for newly diagnosed or previously treated systemic AL amyloidosis with bortezomib, pomalidomide and dexamethasone regimen. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06342466
Study type Interventional
Source Peking University People's Hospital
Contact Yang Liu, Dr
Phone 86-13716926210
Email pkuphliuyang@vip.sina.com
Status Recruiting
Phase Phase 2
Start date May 6, 2024
Completion date December 2026

See also
  Status Clinical Trial Phase
Completed NCT03678259 - 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis Phase 1/Phase 2
Recruiting NCT04006223 - The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Recruiting NCT05951816 - A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis Phase 1
Recruiting NCT06186167 - Amyloidosis Incidence in High-Risk Cardiac Device Patients
Recruiting NCT05150353 - Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP) N/A
Active, not recruiting NCT05968846 - Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load Phase 2